SNDX Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1395937 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY159.7%
TTM net income YoY32.8%
TTM EPS YoY34.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-61.7%
Net margin-72.3%
FCF margin—
EBITDA margin-55.5%
Returns
ROE-426.4%
ROA-33.7%
ROIC (approx.)—
Asset turnover0.47x
Leverage & solvency
Liabilities / assets102.5%
Debt / equity—
Current ratio4.69x
Interest coverage-44,660.00x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $172.35M | $23.68M |
| R&D expense | $258.78M | $241.65M |
| SG&A expense | $179.68M | $120.88M |
| Operating income | -$273.08M | -$339.67M |
| Interest expense | $6,000 | -$1,000 |
| Income tax | $433,000 | — |
| Net income | -$285.42M | -$318.76M |
| EBITDA | -$267.08M | -$331.67M |
| EPS (basic) | -3.29 | -3.72 |
| EPS (diluted) | -3.29 | -3.72 |
| Weighted avg. shares (diluted) | 86.63M | 85.62M |
| Balance sheet | ||
| Cash & equivalents | $134.93M | $154.08M |
| Short-term investments | $259.14M | $418.80M |
| Receivables | $38.00M | $7.60M |
| Inventory | $32.75M | $366,000 |
| Current assets | $528.08M | $603.06M |
| PP&E, net | $181,000 | $0 |
| Total assets | $529.71M | $724.82M |
| Current liabilities | $120.12M | $103.55M |
| Short-term debt | $343.91M | $343.68M |
| Total liabilities | $465.08M | $436.69M |
| Shareholders' equity | $64.63M | $288.12M |
| Shares outstanding | 87.41M | 85.69M |
| Cash flow statement | ||
| Operating cash flow | -$322.98M | -$274.90M |
| Capital expenditure | $187,000 | $0 |
| Free cash flow | -$323.17M | -$274.90M |
| Investing cash flow | $290.04M | -$219.78M |
| Financing cash flow | $13.68M | $353.37M |
| Depreciation & amortization | $6.00M | $8.00M |
| Stock-based compensation | $47.50M | $43.03M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.